Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M.K. Menon is active.

Publication


Featured researches published by M.K. Menon.


European Journal of Pharmacology | 1978

Comparison of the dopaminergic effects of apomorphine and (-)-N-n-propylnorapomorphine.

M.K. Menon; William G. Clark; John L. Neumeyer

(-)-N-n-propylnorapomorphine (NPA) was found to be 2.3 times more active than apomorphine in producing stereotypy in novice mice. This potency ratio was not changed by reserpine pretreatment (4 h prior). However, when mice pretreated with reserpine 24 h earlier were used, NPA was found to be 6.5 times more active in producing locomotor stimulation and 8.7 times more active in producing stereotypy than apomorphine. In these mice, a second dose of reserpine or alpha-methyl-p-tyrosine (alphaMT) given 4 h prior to NPA administration considerably reduced the locomotor effects of NPA. Such treatments did not modify the effects of apomorphine. Phenoxybenzamine failed to alter the responses of both these drugs. It was concluded that, while apomorphine possesses direct dopamine (DA) receptor stimulant effect, that of NPA is partly direct and partly indirect in nature. In novice mice, NPA was 91 times more active than apomorphine in inhibiting the alphaMT-induced depletion of brain DA. The question is raised why the powerful DA receptor agonistic effect of NPA did not produce equivalent behavioral responses in mice. The likely explanation would be that, in addition to its effect on the striatonigral DA system from which the stereotypic response originates, NPA also exerts a predominant effect on the mesolimbic areas. The combined effect of NPA on these two components of the DA system is reflected in the biochemical results. The overall dopaminergic effect of NPA is several times greater than that of apomorphine.


Neuropharmacology | 1986

An in vivo pharmacological method for the quantitative evaluation of the central effects of alpha1 adrenoceptor agonists and antagonists

M.K. Menon; C.K. Kodama; A.S. Kling; J. Fitten

A new in vivo pharmacological method for the quantitative evaluation of alpha 1-adrenoceptor agonists and antagonists has been developed. It consists of recording the myoclonic twitch activity (MTA) of the suprahyoideal muscle of rats anesthetized with urethane. In these animals, the isomers of amphetamine elicited myoclonic twitch activity; their effects were dose-related and the d-isomer was approximately 3.5 times more effective than the l-isomer. While pimozide did not block this response, the postsynaptic alpha 1-antagonist prazosin fully blocked the myoclonic twitch activity induced by d-amphetamine. Other postsynaptic alpha 1-antagonists, such as haloperidol, phenoxybenzamine and clozapine, were also effective in blocking this response to d-amphetamine. Since d-amphetamine elicited myoclonic twitch activity in rats pretreated with reserpine and alpha-methyl-p-tyrosine, it was concluded that d-amphetamine exerted a direct alpha 1-adrenoceptor stimulation. In rats pretreated with nialamide and pimozide, l-DOPA elicited myoclonic twitch activity which was dose-related. This effect of l-DOPA was promptly and fully blocked by prazosin. It was concluded that this response to l-DOPA resulted from stimulation of alpha 1-adrenoceptors. The relative potencies of four alpha 1-adrenoceptor stimulants, namely, cirazoline, St-587, (-)SKF 89748A and Sgd 101/75 were determined using this method. The results correlated very well with their relative potencies to increase the diastolic blood pressure of pithed rats. Evidence that myoclonic twitch activity is a centrally-mediated response has also been presented. It appears that the method is a simple, sensitive, versatile and easily quantifiable procedure for the evaluation of the central effects of alpha 1-adrenoceptor agonists and antagonists.


European Journal of Pharmacology | 1973

Blockade of the central effects of d-amphetamine sulfate by amantadine hydrochloride

M.K. Menon; William G. Clark; R.M. Fleming

Abstract Amantadine hydrochloride, unexpectedly, was found to block certain effects of d-amphetamine sulfate. In mice pretreated with amantadine, 150 mg/kg, d-amphetamine, 2 mg/kg or 5 mg/kg, failed to produce hyperactivity. This pretreatment also protected aggregated mice from the lethal effects of d-amphetamine, 30 mg/kg. Both d-amphetamine, 15 mg/kg, and chlorpromazine hydrochloride, 10 mg/kg, caused elevations in the homovanillic acid (HVA) concentrations in the caudate nucleus of mice, and amantadine pretreatment blocked this response to d-amphetamine but not that to chlorpromazine. Due to the many similarities in the pharmacological, behavioral, biochemical and clinical effects of amantadine and d-amphetamine, they may act at the same receptor and the observed antagonism may be due to a competitive blockade so that d-amphetamine fails to reach its site of action.


Neuropharmacology | 1981

Muscimol-induced myoclonic jerks in mice

M.K. Menon; Charlotte A. Vivonia

Abstract Muscimol produced myoclonic jerks in mice. The manifestation of this response required a minimum dose of 2 mg/kg (i.p.). These jerks, involving the hind quarter of the animals, commenced after a latent period of 6–10 min, were more or less rhythmic, peaked between 27 and 45 min and slowly tapered off thereafter. The maximum responses seen after 2 and 3 mg/kg (i.p.) doses of muscimol were 48 and 76 jerks per min, respectively. It is not known whether the response to muscimol is spinal in origin or whether a metabolite is involved. This effect of muscimol was not blocked by subconvulsive doses of picrotoxin or bicuculline. Drug interaction studies showed that treatments which resulted in decreased activity of the central norepinephrine system, or which enhanced the activity of the central serotoninergic system, effectively blocked the response to muscimol. The present study has not only brought to light a new aspect of the central action of muscimol, but it also seems that this response may prove to be valuable as an animal model for the evaluation of antimyoclonic drugs. One interesting aspect of this response is that it is strain-specific.


European Journal of Pharmacology | 1981

Modification of apomorphine hypothermia by drugs affecting brain 5-hydroxytryptamine function.

M.K. Menon; Charlotte A. Vivonia

Intraperitoneal administration of apomorphine caused hypothermia in mice. Pretreatment with the serotonin (5-HT) receptor antagonists methysergide (3 mg/kg), cinanserin (10 mg/kg) or brom-LSD (3 mg/kg) potentiated this response of apomorphine. Brain 5-HT depletion by p-chlorophenylalanine caused similar modification. On the contrary, the 5-HT receptor agonists quipazine (3 mg/kg) and MK-212 (3 mg/kg), significantly blocked apomorphine hypothermia. It was concluded that 5-HT modulates the dopamine (DA)-mediated body temperature changes and that drug-induced alterations in the brain 5-HT function modify apomorphine-induced hypothermia in a predictable manner. One mg/kg dose of lysergic acid diethylamide (LSD) blocked apomorphine hypothermia. The apomorphine-blocking effect of both quipazine and LSD developed tolerance. Moreover, LSD showed cross tolerance with quipazine. It was concluded that the hypothermia-blocking property of LSD resides on its ability to activate the hypothalamic 5-HT receptors.


Neuropharmacology | 1985

Antagonism of the hypnotic effect of ethanol in mice by an alpha-1 adrenoceptor agonist

M.K. Menon; C.K. Kodama

A lipid soluble alpha 1-adrenoceptor agonist 2-(2-chloro-5-trifluoromethylphenylimino) imidazolidine (St 587) antagonized the hypnotic effect of ethanol in C57Bl/6 and CD-1 mice. In Swiss-Webster mice the effect of St 587 was weak and in BALB/c mice this drug potentiated ethanol hypnosis. St 587 did not enhance the elimination of ethanol. Cirazoline, an alpha 1-adrenoceptor agonist which is more potent than St 587, was relatively more effective in antagonizing the ethanol-induced hypnosis. Though it appears that St 587 exerted its ethanol antagonism by virtue of its alpha 1-adrenoceptor agonistic effect, other contributing factors may also have to be considered. St 587 may prove to be of value in understanding the mechanism of action of ethanol and in the treatment of acute ethanol intoxication.


European Journal of Pharmacology | 1970

Influence of desmethylimipramine on the appetite-lowering effects of d-amphetamine and other anorectics

M.K. Menon; K. Subramanian; Nirmala K. Menon; S.N. Sharma

Abstract The influence of desmethylimipramine (DMI) pretreatment on the anorectic and central stimulant effects of d-amphetamine, phentermine, chlorphentermine, phenmetrazine and diethylpropion in rats were studied. DMI caused marked potentiation and prolongation of the effects of d-amphetamine and diethylpropion, but did not cause any significant change in the effects of the other two drugs. This effect of DMI might be due to its interference on the metabolic inactivation of the above anorectics.


Psychopharmacology | 1983

Evidence for presynaptic antagonism by amantadine of indirectly acting central stimulants

M.K. Menon; Charlotte A. Vivonia; Victor G. Haddox

In mice, amantadine pretreatment (150 mg/kg, but not 10 mg/kg, 2h prior to testing) markedly inhibited the locomotor stimulation produced by submaximal doses of d-amphetamine, amfonelic acid, methylphenidate, caffeine, memantin, phencyclidine, and cocaine. A 50-mg/kg dose was ineffective in blocking the effects of caffeine and memantin, but blocked the responses to the other five stimulants. Amantadine did not modify the locomotor stimulant effect of apomorphine in reserpinized mice. These results indicate that amantadine acts as a presynaptic antagonist to the above seven stimulants. Even the highest dose of amantadine did not modify the hyperactivity induced in mice by morphine and levorphanol. This result is consistent with evidence showing opiate actions at postsynaptic striatal neurons, sites where presumably amantadine is unable to exert an antagonist effect. Amantadine did not modify the central depressant effects of ethyl alcohol and pentobarbital. Amantadine could be of value as a pharmacological tool in understanding the mode of action of central stimulants, and in the management of stimulant abuse. The present data do not support the currently held view that the antiparkinsonism effect of amantadine results from its ability to potentiate the central effects of dopamine.


Neuropharmacology | 1984

Suitability of amfonelic acid-induced locomotor stimulation in mice as a model for the evaluation of classical and atypical antipsychotics

M.K. Menon; V.G. Haddox

The potential usefulness of amfonelic acid ( AFA ), a selective dopamine (DA)-releasing agent, in quantitatively assessing the antidopaminergic and antipsychotic potencies of drugs, was evaluated. The procedure consisted of determining the ED50S of a number of neuroleptics in inhibiting the locomotor-stimulant effect of amfonelic acid in mice. These results were compared with the published data on the relative potencies of the neuroleptics to induce catalepsy in rats, to block drug-induced stereotypy and to alleviate psychotic symptoms clinically. It was observed that the amfonelic acid model was as good as, but not superior to, the other three procedures in identifying the potencies of classical antipsychotics. This model, however, was able to predict the clinical effectiveness of two atypical antipsychotics, thioridazine and clozapine, much more accurately than could be achieved by the other methods. Certain other atypical antipsychotics such as, mezilamine , RMI 81, 582, sulpiride and sultopride also produced a dose-related blockade of the amfonelic acid induced locomotor stimulation in mice. The antagonism to amfonelic acid exhibited by mezilamine was weaker, and that of RMI 81,582 was stronger than that of chlorpromazine. Only large doses of the two benzamides were effective in blocking the effect of amfonelic acid, sultopride being about 3 times more effective than sulpiride in this regard. Another analogue of benzamide, YM-09151-2, known to have the profile of a classical antipsychotic, was more effective than haloperidol in blocking the stimulant effect of amfonelic acid. Trebenzomine , which is considered to have the properties of an atypical antipsychotic, although this was proved otherwise when tested clinically, actually potentiated the response of mice to amfonelic acid. Apomorphine antagonized the stimulant effect of amfonelic acid, which could be attributed to its agonist activity at presynaptic DA receptors. Apomorphine has been reported to have clinical antipsychotic effects. Certain non-antipsychotic drugs such as prazosin (but not phenoxybenzamine), promethazine, methysergide, diazepam, as well as the gamm -aminobutyric acid agonists, muscimol and THIP, also inhibited the amfonelic acid-induced locomotor stimulation. In spite of this drawback, the present procedure should prove to be a useful animal model for the evaluation of the antipsychotic potencies of drugs. Its ability to identify the potential usefulness of atypical antipsychotics is noteworthy.


Neuropharmacology | 1984

Pharmacological studies on the antagonism by antidepressants of the hypothermia induced by apomorphine

M.K. Menon; Charlotte A. Vivonia; A.S. Kling

In male Swiss mice, the hypothermia induced by apomorphine (10 mg/kg) was completely blocked by administration of haloperidol and d-butaclamol, but not by l-butaclamol, phenoxybenzamine, clozapine or propranolol. This substantiated the dopaminergic nature of the hypothermia induced by apomorphine. Desipramine, imipramine, chlorimipramine, fluoxetine and mazindol produced a dose-dependent blockade of apomorphine-induced hypothermia, their ED50S being 0.313, 0.733, 1.88, 6.04 and 0.0033 mg/kg, respectively. Iprindole failed to block the hypothermia induced by apomorphine. Because chlorimipramine and fluoxetine, which are relatively more selective and more potent blockers of the uptake of serotonin (5-HT) than is desipramine, were considerably less effective than the latter in antagonizing hypothermia induced by apomorphine, it was concluded that the property of blocking uptake of 5-HT alone does not contribute to the antagonism to apomorphine exhibited by the classical antidepressants. Quipazine, a 5-HT agonist, blocked the hypothermia induced by apomorphine, this effect developed tolerance on repeated administration. However, no cross-tolerance between quipazine and the antidepressants could be demonstrated. This finding provided further support for the non-involvement of 5-HT in the antagonism to apomorphine. No correlation existed between the potencies of these antidepressants to block the reuptake of norepinephrine (NE) in brain and their relative potencies to block the hypothermia induced by apomorphine. Moreover, selective depletion of high affinity binding sites for [3H]desipramine and [3H]-NE, achieved by treatment with DSP-4, failed to reduce the effectiveness of desipramine in blocking the hypothermia induced by apomorphine. Hence, inhibition of uptake of NE does not account for the antagonism by the antidepressants of apomorphine-induced hypothermia. A possibility was considered that certain antidepressants selectively blocked the hypothalamic DA receptors, thereby antagonizing the hypothermic effects of apomorphine, leaving the extra-hypothalamic dopaminergic responses of this DA agonist unaffected.

Collaboration


Dive into the M.K. Menon's collaboration.

Top Co-Authors

Avatar

Charlotte A. Vivonia

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

William G. Clark

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

C.K. Kodama

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

A.S. Kling

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

Dorothea Aures

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

J. Fitten

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

J.T. Cummins

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

K von Hungen

United States Department of Veterans Affairs

View shared research outputs
Top Co-Authors

Avatar

K. Subramanian

United States Department of Veterans Affairs

View shared research outputs
Researchain Logo
Decentralizing Knowledge